Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
25.82
+4.35 (20.26%)
NASDAQ · Last Trade: Apr 29th, 1:43 PM EDT
Detailed Quote
Previous Close
21.47
Open
22.55
Bid
25.78
Ask
25.87
Day's Range
22.23 - 26.07
52 Week Range
17.38 - 28.15
Volume
1,168,269
Market Cap
1.85B
PE Ratio (TTM)
-42.33
EPS (TTM)
-0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
624,080
Chart
About Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
Kiniksa Pharmaceuticals International Plc is a biotechnology company focused on developing innovative therapies for autoimmune and rare diseases. The company is engaged in advancing its pipeline of novel product candidates that target critical unmet medical needs, leveraging its expertise in immunology and inflammation. Kiniksa aims to bring effective treatments to patients through rigorous research and developmental strategies, seeking to improve the quality of life for individuals affected by challenging health conditions. Read More
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease –
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldn’t ignore.
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldn’t ignore.
KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
